The most common TEAEs in the tislelizumab arm were decreased hematologic indexes (anemia, neutropenia, thrombocytopenia, and leukopenia), increased alanine transaminase (ALT), increased aspartate transaminase (AST), nausea, and decreased appetite, but there were slightly fewer TEAEs than in the control arm [19–21]. This evidence concerns the gene GPT and Decreased total neutrophil count.